Skip to main content

Empaveli News

Apellis Announces U.S. FDA Approval of the Empaveli Injector, a Device to Streamline Self-Administration

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the Empaveli® Injector. ...

FDA Approves Empaveli (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S....

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Empaveli patient information at Drugs.com